-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215

Benzinga·07/31/2026 13:58:51
语音播报
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $215.